ERBB2 and breast carcinoma: In the PerELISA trial, Guarneri et al. evaluated the ability of HER2DX to predict the efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in postmenopausal women with stage II and IIIA HER2-positive/HR-positive breast cancer that is highly estrogen-sensitive.